www.us.adakveo.com Open in urlscan Pro
172.64.154.154  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content

This site is for US residents only.
 * Prescribing Information

ADAKVEO
 

ADAKVEO IS A 30-MINUTE IV INFUSION GIVEN ONCE PER MONTH AFTER YOUR SECOND DOSE



 * You will receive your first infusion, and then a second infusion 2 weeks
   later

 * After that, you will be given an IV infusion every 4 weeks

 * If you miss an appointment for your infusion, contact your doctor or health
   care provider as soon as possible to reschedule

 * Your health care provider may also prescribe other treatments for you to take
   during treatment with ADAKVEO

 * Do not stop receiving ADAKVEO unless your health care provider tells you to

 

FINANCIAL RESOURCES

 

ADAKVEO SUPPORT TO HELP YOU ON YOUR JOURNEY

The ADAKVEO Support at PANO program may be able to assist you with accessing
your medicine—from insurance verification to financial assistance information
through a knowledgeable call center.

Novartis is committed to support you as you begin treatment with ADAKVEO,
according to your doctor's prescribed treatment. ADAKVEO Support at PANO offers
resources and support designed specifically to help you with the process.

ADAKVEO Support at PANO offers the following services:

 * Help you understand your insurance coverage and financial responsibilities
   throughout the insurance verification process

 * Help identify infusion sites covered by your insurance plan

 * Information about financial assistance that may be available*

 * Patient Support Counselors who are able to provide information in more than
   160 languages

 * One single point of contact to help guide you through getting access to
   ADAKVEO

SERVICE REQUEST FORM (SRF)

The SRF is a single form with 2 halves:

 * One half to be completed by you or your caregiver

 * One half to be completed by your doctor

Both halves must be fully completed and submitted to start the process. ADAKVEO
Support at PANO will then match the 2 halves and contact your doctor to initiate
next steps.
TO LEARN MORE, CALL 1-800-282-7630.

SAVE WITH THE UNIVERSAL CO-PAY PROGRAM

 

You may be eligible for immediate co-pay savings on your next prescription of
ADAKVEO.

 

 * Eligible patients with private/commercial insurance may pay as little as $0
   for your ADAKVEO treatment each month

 * Novartis will pay the remaining co-pay, up to $15,000 per calendar year†

 

To learn more, call 1-800-282-7630.

*Novartis Pharmaceuticals Corporation does not guarantee success in obtaining
coverage or financial assistance. Third-party payment for medical products and
services is affected by numerous factors, not all of which can be anticipated or
resolved.

†Limitations apply. This offer is only available to patients with private
insurance. The program is not available for patients who are enrolled in
Medicare, Medicaid, or any other federal or state health care program. Novartis
reserves the right to rescind, revoke, or amend this program without notice.

For full Terms and Conditions, visit Copay.NovartisOncology.com or call
1-877-577-7756.


IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ADAKVEO?

ADAKVEO may cause serious side effects, including infusion-related reactions. 

Infusion-related reactions. Infusion-related reactions may happen during or
within 24 hours of receiving an infusion of ADAKVEO. Your health care provider
may...

APPROVED USE

What is ADAKVEO® (crizanlizumab-tmca)?

ADAKVEO is a prescription medicine used in people 16 years of age and older who
have sickle cell disease to help reduce how often painful crises happen.

It is not known if ADAKVEO is safe and effective in children under 16 years of
age...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE
Reference: 1. ADAKVEO. Prescribing Information. Novartis Pharmaceuticals Corp.
 * Medical Information
 * Contact Us
 * Non-US Residents

ADAKVEO is a registered trademark of Novartis AG.

Use of website is governed by the Terms of Use and Privacy Policy. 


Copyright © 2023 Novartis Pharmaceuticals Corporation. All rights reserved.

10/23     305539

Back to top



YOU ARE ABOUT TO LEAVE ADAKVEO.COM


You are about to leave a Novartis site and continue to an external website
independently operated and not managed by Novartis Pharmaceuticals Corporation.
Continue to External Site

YOU ARE ABOUT TO LEAVE ADAKVEO.COM


You are now being directed to another Novartis website.
Continue to External Site